Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADCT 901 (Primary)
  • Indications Advanced breast cancer; Cholangiocarcinoma; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics

    • Most Recent Events

    • 04 Jan 2024 According to an ADC Therapeutics media release, the Company has decided to discontinue this program due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs.
    • 04 Jan 2024 Status changed from recruiting to discontinued, according to an ADC Therapeutics media release.
    • 08 Aug 2023 According to an ADC Therapeutics media release, study protocol amendment to explore different dosing schedules has been finalized and submitted to the FDA and will be submitted shortly to the regulatory authorities in Europe. Once IRB approved the protocol, the Company plans to advance to the next dosing level. The IHC assay is under final validation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top